ClinicalTrials.Veeva

Menu

Vibrational Therapy to Improve Gait and Balance in Parkinson's Disease

Virginia Commonwealth University (VCU) logo

Virginia Commonwealth University (VCU)

Status

Withdrawn

Conditions

Parkinson Disease

Treatments

Device: PDVibe2

Study type

Interventional

Funder types

Other

Identifiers

NCT03872115
HM20015593-P1

Details and patient eligibility

About

The purpose of this research study is to determine optimum dose of vibration delivered by an experimental device called PDVibe2 required to treat freezing of gait in persons with Parkinson's disease (PD). The PDVibe2 was developed by Resonate Forward, LLC (RF). This PDVibe2 was designed to administer vibration therapy to the wearer to improve gait and balance in persons with PD while wearing the device.

Full description

Participation will require up to 8 treatment sessions within 5 days (no more than 2 sessions in one day) plus an additional day for screening and another for follow-up (7 days total). All visits will occur at the Virginia Commonwealth University Parkinson's Movement and Disorders Center in Richmond, VA. Participants will be asked to walk for a brief period of time while wearing the PDVibe2. The PDVibe2 will provide vibration therapy and study staff will measure the number of "freezes" before, during and after therapy. Participants will be asked to provide feedback on the device, the therapy session and how they are feeling.

Sex

All

Ages

21 to 95 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • age 21 years or older
  • PD diagnosed by a movement disorder specialist for 3 months or longer prior to recruitment
  • PD medication regimen is stable over the last 3 months with no changes
  • Hoehn & Yahr stage 2 (N = 13) and H&Y stage 3 (N=13),
  • able to walk independently or with a simple assistive device (e.g., cane, walker)
  • observed by the research team to have PD related gait disturbance such as FOG, shortened or irregular stride lengths, irregular step cadence, slowed speed while on their regular treatment regimen.

Exclusion criteria

  • diagnosed with a known Parkinson plus syndrome
  • were previously exposed to vibration treatment for gait and balance
  • presence of dementia (Montreal Cognitive Assessment < 21)
  • additional disorders (not related to PD)impairing gait, stance, balance or coordination (e.g. stroke, leg amputations, or multiple sclerosis)
  • history of implantable cardiac device or any other implanted electronic device except a deep brain stimulator (DBS)
  • use of braces/orthotics that assist with walking
  • are currently in physical therapy (PT) treatment for balance or gait
  • peripheral neuropathy by exam
  • any condition that, in the opinion of the PIs, would compromise participant safety, data integrity, or data interpretation.
  • Children under the age of 18
  • Prisoners
  • Women who are pregnant or may become pregnant during the course of this study since the safety of this device for an unborn child is unknown.

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

0 participants in 9 patient groups

Setting 1
Experimental group
Description:
PDVibe2 set to high frequency and low amplitude
Treatment:
Device: PDVibe2
Setting 2
Experimental group
Description:
PDVibe2 set to high frequency and medium amplitude
Treatment:
Device: PDVibe2
Setting 3
Experimental group
Description:
PDVibe2 set to high frequency and high amplitude
Treatment:
Device: PDVibe2
Setting 4
Experimental group
Description:
PDVibe2 set to medium frequency and low amplitude
Treatment:
Device: PDVibe2
Setting 5
Experimental group
Description:
PDVibe2 set to medium frequency and medium amplitude
Treatment:
Device: PDVibe2
Setting 6
Experimental group
Description:
PDVibe2 set to medium frequency and high amplitude
Treatment:
Device: PDVibe2
Setting 7
Experimental group
Description:
PDVibe2 set to low frequency and low amplitude
Treatment:
Device: PDVibe2
Setting 8
Experimental group
Description:
PDVibe2 set to low frequency and medium amplitude
Treatment:
Device: PDVibe2
Setting 9
Experimental group
Description:
PDVibe2 set to low frequency and high amplitude
Treatment:
Device: PDVibe2

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems